October 25, 2019 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Approval of minutes from July 25, 2019 (vote required)
2. Approval of minutes from July 25, 2019 (vote required)
»
3. New business:
Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): » - a. Androgenic agents, topical b. Antibiotics, gastrointestinal (GI) c. Antibiotics, topical d. Antibiotics, vaginal e. Anticonvulsants (class will not be reviewed but Board will hear public testimony) f. Antiemetics/antivertigo agents g. Antifungals, oral h. Antifungals, topical i. Antihistamines - first generation j. Antiparasitics, topical k. Antipsychotics l. Antivirals, topical m. Bone resorption suppression and related agents n. Colony stimulating factors o. Cytokine and Cell Adhesion Molecule (CAM) antagonists p. Epinephrine, self-injected q. GI motility, chronic r. Growth hormone s. Hepatitis C agents t. Hypoglycemics, incretin mimetics/enhancers u. Hypoglycemics, insulin and related agents v. Hypoglycemics, meglitinides w. Hypoglycemics, metformin x. Hypoglycemics, sodium-glucose cotransporter-2 inhibitors (SGLT2) y. Hypoglycemics, thiazolidinedione (TZD) z. Macrolides/Ketolides aa. aa.Opiate dependence treatments ab. bb.Penicillins ac. cc.Tetracyclines
3. New business: Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): »
a. Androgenic agents, topical b. Antibiotics, gastrointestinal (GI)
c. Antibiotics, topical
d. Antibiotics, vaginal
e. Anticonvulsants (class will not be reviewed but Board will hear public testimony)
f. Antiemetics/antivertigo agents
g. Antifungals, oral
h. Antifungals, topical
i. Antihistamines - first generation
j. Antiparasitics, topical
k. Antipsychotics
l. Antivirals, topical
m. Bone resorption suppression and related agents
n. Colony stimulating factors
o. Cytokine and Cell Adhesion Molecule (CAM) antagonists
p. Epinephrine, self-injected
q. GI motility, chronic
r. Growth hormone
s. Hepatitis C agents
t. Hypoglycemics, incretin mimetics/enhancers
u. Hypoglycemics, insulin and related agents
v. Hypoglycemics, meglitinides
w. Hypoglycemics, metformin
x. Hypoglycemics, sodium-glucose cotransporter-2 inhibitors (SGLT2)
y. Hypoglycemics, thiazolidinedione (TZD)
z. Macrolides/Ketolides
aa. aa.Opiate dependence treatments
ab. bb.Penicillins
ac. cc.Tetracyclines
»
4. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: » - a. Emgality Syringe 100 mg / Antimigraine Agents, Other b. Tadalafil / Benign Prostatic Hyperplasia (BPH) Treatments c. Katerzia / Calcium Channel Blockers d. Cutaquig / Immune Globulins e. Ezallor Sprinkle / Lipotropics, Statins f. Lidopure, Zilacaine Patch / Neuropathic Pain g. Beser Kit / Steroids, Topical Medium h. Adhansia XR, Evekeo ODT, Jornay PM, Sunosi / Stimulants and Related Agents
4. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: »
a. Emgality Syringe 100 mg / Antimigraine Agents, Other b. Tadalafil / Benign Prostatic Hyperplasia (BPH) Treatments
c. Katerzia / Calcium Channel Blockers
d. Cutaquig / Immune Globulins
e. Ezallor Sprinkle / Lipotropics, Statins
f. Lidopure, Zilacaine Patch / Neuropathic Pain
g. Beser Kit / Steroids, Topical Medium
h. Adhansia XR, Evekeo ODT, Jornay PM, Sunosi / Stimulants and Related Agents
»
5. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
5. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
»
6. Executive work session
Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
6. Executive work session Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
»
7. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
7. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
»
8. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) » - a. Atypical antipsychotics – long-acting injectables b. Atypical antipsychotics – oral c. Insulins d. Nitazoxanide e. Promethazine use in children 2 years of age or younger f. Quetiapine, low-dose
8. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) »
a. Atypical antipsychotics – long-acting injectables b. Atypical antipsychotics – oral
c. Insulins
d. Nitazoxanide
e. Promethazine use in children 2 years of age or younger
f. Quetiapine, low-dose
»
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Respiratory Disease Management b. Report on recent retrospective DUR intervention outcomes: i. Diabetes Disease Management 2018 ii. Rheumatoid Arthritis Management 2018 iii. Opioid Prescribing c. Retrospective DUR proposals (vote required) i. Opioid/Benzodiazepine/Antipsychotics (Support Act) ii. Pain Management with Opioids
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Respiratory Disease Management
b. Report on recent retrospective DUR intervention outcomes:
i. Diabetes Disease Management 2018
ii. Rheumatoid Arthritis Management 2018
iii. Opioid Prescribing
c. Retrospective DUR proposals (vote required)
i. Opioid/Benzodiazepine/Antipsychotics (Support Act)
ii. Pain Management with Opioids
»
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) » - a. Bonjesta/Diclegis (doxylamine/pyridoxine) – new criteria b. Cytokine and CAM Antagonists – addition of Rinvoq (upadacitinib) c. Diacomit (stiripentol) – new criteria d. Sunosi (solriamfetol) – addition of Sunosi to current Provigil/Nuvigil criteria
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) »
a. Bonjesta/Diclegis (doxylamine/pyridoxine) – new criteria b. Cytokine and CAM Antagonists – addition of Rinvoq (upadacitinib)
c. Diacomit (stiripentol) – new criteria
d. Sunosi (solriamfetol) – addition of Sunosi to current Provigil/Nuvigil criteria
»
Items 11 & 12 » - 11. Next meeting date: January 24, 2020 12. Adjourn
Items 11 & 12 »
11. Next meeting date: January 24, 2020 12. Adjourn
